Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

14.82
+0.19001.30%
Post-market: 14.820.00000.00%17:44 EST
Volume:1.92M
Turnover:28.52M
Market Cap:4.66B
PE:921.01
High:14.99
Open:14.65
Low:14.57
Close:14.63
52wk High:15.00
52wk Low:6.69
Shares:314.36M
Float Shares:168.50M
Volume Ratio:1.05
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0161
EPS(LYR):-0.3783
ROE:-881.26%
ROA:6.79%
PB:-42.56
PE(LYR):-39.18

Loading ...

BRIEF-Amneal Pharma Says On Feb 2nd, Co Enters Amendment No. 2 To Term Loan Credit Agreement - SEC Filing

Reuters
·
Feb 03

Amneal Pharma: Amneal Pharma - Consenting Lenders Converted Existing Term Loans Into New Term Loans With an Amount of $1.96 Bln-SEC Filing

THOMSON REUTERS
·
Feb 03

Amneal Pharma - on Feb 2Nd, Co Enters Amendment No. 2 to Term Loan Credit Agreement - SEC Filing

THOMSON REUTERS
·
Feb 03

Amneal Pharmaceuticals senkt Zinsmarge bei bestehendem Terminkredit um 50 Basispunkte

Reuters
·
Feb 03

BRIEF-Amneal Pharma To Settle Majority Of Opioids-Related Claims

Reuters
·
Jan 29

Amneal Pharmaceuticals Settles Opioid Lawsuits for $88.5 Million and Naloxone Donations

Reuters
·
Jan 29

Amneal Pharma - to Provide $177.4 Mln in Naloxone Nasal Spray to Help Treat Opioid Overdoses - SEC Filing

THOMSON REUTERS
·
Jan 29

Amneal Pharma - to Pay $88.5 Mln Under Opioids Settlement - SEC Filing

THOMSON REUTERS
·
Jan 29

BUZZ-Amneal Pharma gains as co poised to join S&P SmallCap index

Reuters
·
Jan 28

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

GlobeNewswire
·
Jan 27

Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum

Simply Wall St.
·
Jan 22

Amneal Pharma: Expects to Meet or Exceed Its 2025 Full-Year Financial Guidance

THOMSON REUTERS
·
Jan 13

Amneal Pharmaceuticals Inc FY2025 Shr View $0.80, REV View $3.01 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 13

Amneal Pharmaceuticals Expects to Meet or Exceed 2025 Financial Guidance

Reuters
·
Jan 13

Amneal Pharmaceuticals Announces Plans to Launch Accessibility Index and Expand Efforts to Improve Medicine Affordability, Availability, Innovation, and Knowledge

Reuters
·
Jan 13

BRIEF-KeifeRX Announces Research Collaboration & Option Agreement With Amneal Pharmaceuticals

Reuters
·
Jan 10

Keiferx: Financial Terms of Agreement Were Not Disclosed

THOMSON REUTERS
·
Jan 10

Keiferx Announces Research Collaboration and Option Agreement With Amneal Pharmaceuticals to Advance Kfrx06, a Brain-Penetrant Lrrk2 Program for Parkinson’s Disease

THOMSON REUTERS
·
Jan 10

Amneal Pharmaceuticals Partners with KeifeRx to Advance LRRK2 Inhibitor for Parkinson’s Disease

Reuters
·
Jan 10

Truist Securities Adjusts Price Target on Amneal Pharmaceuticals to $15 From $14, Maintains Buy Rating

MT Newswires Live
·
Jan 07